Medications not yet evaluated by P&T are considered NON-FORMULARY . . . . . Always check 2 unique patient identifiers - NAME and DATE OF BIRTH - at every step! . . . . . Please be sure to document all clinical activities daily.
Search results for:

alendronate

alendronate
Drug Name Form Strength Formulary Unrestricted Formulary Restricted Non-Formulary Interchange
Fosamax SOLUTION, ORAL 70 mg/75 mL      
Binosto TABLET, EFFERVESCENT, ORAL 70 mg      
Fosamax TABLET, ORAL 5 mg, 10 mg, 40 mg, 70 mg      
Fosamax TABLET, ORAL 35 mg      
VIEW MORE Miscellaneous Therapeutic Agents
CLASS
920000
Comments:

Binosto medication guide

Fosamax medication guide

Automatic discontinuation of oral bisphosphonates for inpatients due to safety risk involving patient required to remain in upright position for at least 30 minutes, to take with a full glass of water, to hold food, other liquids and drugs for at least 30 minutes after dose, and several other issues. Exception: alendronate 35 mg stocked for rare cases of Paget's Disease.

Reviewed: January 27, 2009 and June 26, 2012 (Binosto)

Last updated: Dec. 19, 2017






This site is intended for the staff of Huntsville Hospital.
While others may view accessible pages, Huntsville Hospital makes no warranty, express or implied,
as to the use of this information outside of Huntsville Hospital.
Please note than many documents are accessible via the provided link
only when connected to the Huntsville Hospital intranet.

Copyright © 2024 Rpharmy, LLC ­ All Rights Reserved